Result of AGM

BioPharma Credit PLC
12 June 2024
 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

 

RESULT OF 2024 ANNUAL GENERAL MEETING

 

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed by way of a poll.

 

 

Resolutions

Votes

For

%

Votes Against

%

Total Votes

% of Total Voting Rights Voted

Votes Withheld1

1: To receive and accept the annual report and financial statements

558,898,973

99.99%

52,892

0.01%

558,951,865

45.85%

28,112

2: To approve the Directors' Remuneration Report

558,576,994

99.97%

177,879

0.03%

558,754,873

45.83%

225,104

3: To receive and approve the Directors' Remuneration Policy

558,551,021

99.96%

227,616

0.04%

558,778,637

45.84%

201,340

4: To re-elect Harry Hyman as a Director

494,888,417

99.99%

66,478

0.01%

494,954,895

40.60%

64,025,082

5: To re-elect Colin Bond as a Director

558,759,159

99.99%

76,104

0.01%

558,835,263

45.84%

144,714

6: To re-elect Duncan Budge as a Director

494,888,417

88.56%

63,946,846

11.44%

558,835,263

45.84%

144,714

7: To re-elect Stephanie Léouzon as a Director

558,780,785

99.99%

54,478

0.01%

558,835,263

45.84%

144,714

8: To re-elect Sapna Shah as a Director

558,780,762

99.99%

54,478

0.01%

558,835,240

45.84%

144,737

9: To re-elect Rolf Soderstrom as a Director

558,744,159

99.99%

76,104

0.01%

558,820,263

45.84%

159,714

10: To re-appoint Ernst & Young LLP as Auditor to the Company

558,682,815

99.96%

204,636

0.04%

558,887,451

45.84%

92,526

11: To authorise the Directors to determine the remuneration of the Auditor

558,769,161

99.99%

69,478

0.01%

558,838,639

45.84%

141,338

12: To approve the Company's dividend payment policy

558,978,176

100.00%

1,801

0.00%

558,979,977

45.85%

0

13: To authorise the allotment of shares by the Company

556,785,857

99.62%

2,150,350

0.38%

558,936,207

45.85%

43,770

14: To authorise the disapplication of pre-emption rights

556,858,554

99.63%

2,077,653

0.37%

558,936,207

45.85%

43,770

15: To authorise the Company to make market purchases

of ordinary shares

558,895,163

99.98%

84,814

0.02%

558,979,977

45.85%

0

16: To authorise the Company to hold general meetings

on 14 clear days' notice

558,867,851

99.98%

99,598

0.02%

558,967,449

45.85%

12,528

 

1.     A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

 

Copies of resolutions 13 to 16 have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

12 June 2024

 

 

Enquiries

 

BioPharma Credit plc

 

via Link Company Matters Limited

 

Company Secretary

 

T. +44 (0) 333 300 1950  

 

Buchanan

 

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

 

+44 (0) 20 7466 5000

 

biopharmacredit@buchanan.uk.com

 

 

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

 

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings